The MarketWatch News Department was not involved in the creation of this content. -- A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic ...

The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a ...

PSMA-PET quantification required labor-intensive semiautomated software not in routine use. The study enrolled a high-risk metastatic castration-resistant prostate cancer subgroup, limiting ...

Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, ...

Real-world treatment patterns with lutetium-177-PSMA-617 (177-Lu-PSMA) in patients with metastatic castrate-resistant prostate cancer (mCRPC). CI = Confidence Interval, HR = Hazard Ratio, mut = ...

PSMA-617 to androgen deprivation therapy (ADT) with androgen receptor pathway inhibitor (ARPI) bettered disease control in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according ...

Toronto, Ontario (Embargoed until 9:30 a.m. EDT, Sunday, June 9, 2024)—New data on prolonged prostate-specific antigen (PSA) progression and adverse events grouped by safety topic of interest from the ...

The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness ...

Using an ARPI or taxane after 177Lu-PSMA-617 can produce a robust PSA response in patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu-PSMA-617) was approved in 2022 for patients with metastatic ...

Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting ...

A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ...